Anselm Wong1,2,3, Kennon Heard4,5, Andis Graudins6,7, Richard Dart8, Marco L A Sivilotti9. 1. School of Clinical Sciences, Department of Medicine, Monash University, Melbourne, Victoria, Australia. anselm.wong@austin.org.au. 2. Centre for Integrated Critical Care, University of Melbourne, Melbourne, Victoria, Australia. anselm.wong@austin.org.au. 3. Victorian Poisons Information Centre and Austin Toxicology Service, Austin Hospital, Heidelberg, Victoria, 3084, Australia. anselm.wong@austin.org.au. 4. Rocky Mountain Poison and Drug Center, Denver Health and Hospitals, Denver, CO, USA. 5. Section of Medical Pharmacology and Toxicology, Department of Emergency Medicine, University of Colorado, Aurora, CO, USA. 6. School of Clinical Sciences, Department of Medicine, Monash University, Melbourne, Victoria, Australia. 7. Monash Toxicology Service, Monash Health, School of Clinical Sciences, Department of Medicine, Monash University, Melbourne, Victoria, Australia. 8. Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority, Denver, CO, USA. 9. Departments of Emergency Medicine, and of Biomedical & Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
Abstract
INTRODUCTION:Acetaminophen protein adducts in the circulation are a specific biomarker of acetaminophen oxidation, and may be a more sensitive measure of impending hepatic injury following overdose than alanine transaminase (ALT). We performed an exploratory analytical substudy of adducts during a clinical trial (NACSTOP) of abbreviated (12-hour) versus control (20-hour) acetylcysteine to identify any signal of diminished antidotal effectiveness with shortened therapy. METHODS: We measured adducts at 0, 12, and 20 hours from a convenience sample of subjects enrolled in the cluster-controlled NACSTOP trial evaluating a 12-hour ("abbreviated"; 200 mg/kg over 4 hours, 50 mg/kg over 8 hours) vs 20-hour acetylcysteine regimen ("control"; 200 mg/kg over 4 hours, 100 mg/kg over 16 hours). Adducts were assayed using high-performance liquid chromatography/mass spectrometry. RESULTS: Median ALT 20 hours after the initiation of acetylcysteine was 12 U/L (IQR 8,14) in the abbreviated 12-hour regimen group (N = 8), compared with the control group 16 U/L (IQR 11,21; N = 21) (p = 0.46). Adduct concentrations were similarly low in both groups: abbreviated [(0.005 μmol/L, IQR (0,0.14)] and control [(0.005 μmol/L, IQR (0,0.05)] (p = 0.61). CONCLUSIONS: There were minimal to no acetaminophen protein adducts detected. These findings further support discontinuing acetylcysteine when acetaminophen concentrations are low and liver function tests normal after 12 hours of treatment.
RCT Entities:
INTRODUCTION:Acetaminophen protein adducts in the circulation are a specific biomarker of acetaminophen oxidation, and may be a more sensitive measure of impending hepatic injury following overdose than alanine transaminase (ALT). We performed an exploratory analytical substudy of adducts during a clinical trial (NACSTOP) of abbreviated (12-hour) versus control (20-hour) acetylcysteine to identify any signal of diminished antidotal effectiveness with shortened therapy. METHODS: We measured adducts at 0, 12, and 20 hours from a convenience sample of subjects enrolled in the cluster-controlled NACSTOP trial evaluating a 12-hour ("abbreviated"; 200 mg/kg over 4 hours, 50 mg/kg over 8 hours) vs 20-hour acetylcysteine regimen ("control"; 200 mg/kg over 4 hours, 100 mg/kg over 16 hours). Adducts were assayed using high-performance liquid chromatography/mass spectrometry. RESULTS: Median ALT 20 hours after the initiation of acetylcysteine was 12 U/L (IQR 8,14) in the abbreviated 12-hour regimen group (N = 8), compared with the control group 16 U/L (IQR 11,21; N = 21) (p = 0.46). Adduct concentrations were similarly low in both groups: abbreviated [(0.005 μmol/L, IQR (0,0.14)] and control [(0.005 μmol/L, IQR (0,0.05)] (p = 0.61). CONCLUSIONS: There were minimal to no acetaminophen protein adducts detected. These findings further support discontinuing acetylcysteine when acetaminophen concentrations are low and liver function tests normal after 12 hours of treatment.
Authors: Lars E Schmidt; Ditlev N Rasmussen; Tonny S Petersen; Ines M Macias-Perez; Leo Pavliv; Byron Kaelin; Richard C Dart; Kim Dalhoff Journal: Clin Toxicol (Phila) Date: 2018-05-24 Impact factor: 4.467
Authors: Michael H Court; Zhaohui Zhu; Gina Masse; Su X Duan; Laura P James; Jerold S Harmatz; David J Greenblatt Journal: J Pharmacol Exp Ther Date: 2017-06-29 Impact factor: 4.030
Authors: Sarah F Cook; Amber D King; Yan Chang; Gordon J Murray; Hye-Ryun K Norris; Richard C Dart; Jody L Green; Steven C Curry; Douglas E Rollins; Diana G Wilkins Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2015-01-24 Impact factor: 3.205
Authors: Steven C Curry; Angela Padilla-Jones; Anne-Michelle Ruha; Ayrn D O'Connor; A Min Kang; Diana G Wilkins; Hartmut Jaeschke; Kelly Wilhelms; Richard D Gerkin Journal: J Med Toxicol Date: 2019-04-12
Authors: Marco L A Sivilotti; Mark C Yarema; David N Juurlink; Angela M Good; David W Johnson Journal: Ann Emerg Med Date: 2005-09 Impact factor: 5.721
Authors: Angela L Chiew; Geoffrey K Isbister; Katharine A Kirby; Colin B Page; Betty S H Chan; Nicholas A Buckley Journal: Clin Toxicol (Phila) Date: 2017-06-23 Impact factor: 4.467
Authors: Anselm Wong; Natalie Homer; James W Dear; Kay Weng Choy; James Doery; Andis Graudins Journal: Clin Toxicol (Phila) Date: 2018-11-19 Impact factor: 4.467
Authors: Kennon J Heard; Jody L Green; Laura P James; Bryan S Judge; Liza Zolot; Sean Rhyee; Richard C Dart Journal: BMC Gastroenterol Date: 2011-03-14 Impact factor: 3.067